Quality of life and disability in patients with treatment-failure gout

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 1041-1048

  Becker, Michael A ^a   Schumacher, H Ralph ^b   Benjamin, Katy L ^c   Gorevic, Peter ^d   Greenwald, Maria ^e   Fessel, Jeffrey ^f   Edwards, Lawrence ^g   Kawata, Ariane K ^c   Frank, Lori ^c   Waltrip, Royce ^h   Maroli, Allan ^h   Huang, Bill ^h   Sundy, John S ⁱ   Weisman, Michael ^j   Reginato, Antonio ^j   Griffin, Robert ^j   Goldberger, Edward ^j   Simkin, Peter ^j   Morgan, John ^j   Kivitz, Alan ^j   Weitz, Michael ^j   Fung, H S Eugene ^j   Fudman, Edward ^j   Cronin, Mary ^j   Peller, Jeffrey S ^j   Lies, Richard ^j   Block, Joel ^j   Rosenthal, Pamela ^j   Merrill, Joan ^j   Dewees III, Guy ^j   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Desert Medical Advances   (United States)

^f KAISER PERMANENTE MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h Savient Pharmaceuticals   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j NONE

more..

Author keywords

Disability; Gout; Health related quality of life; Patient reported outcomes; Quality of life

Indexed keywords

ALLOPURINOL; COLCHICINE; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; SULFINPYRAZONE; URIC ACID; ANTIGOUT AGENT;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; GOUT; HUMAN; JOINT; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MORBIDITY; OUTCOME ASSESSMENT; PAIN; PERCEPTION; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SHORT FORM 36; TREATMENT FAILURE; URIC ACID BLOOD LEVEL; CLINICAL TRIAL; DAILY LIFE ACTIVITY; HEALTH STATUS; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; SELF EVALUATION;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; SELF ASSESSMENT (PSYCHOLOGY); SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 67449099218     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.071229     Document Type: Article

References (19)

1. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006;8 Suppl:S2.
2. Kim KY, Schumacher HR, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617.
3. Miller AV, Ranatunga SM, Francis ML. Gout [Internet. Accessed January 6, 2009.]. Available from: http://emedicine.medscape.com/article/329958-overview.
4. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991;50:263-6.
5. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
6. Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 2007;9:258-64.
7. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008;58:2882-91.
8. Ware JE, Snow KK, Kosinski MK, Gandek B. SF-36 health survey: Manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
9. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
10. Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 2008;59:665-9.
11. Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther 2004;6:R505-R513.
12. Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract 2006;60:1210-7.
13. Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry 2001;158:848-56.
14. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes 2004;2:51.
15. Stolwijk-Swuste JM, Beelen A, Lankhorst G, Nollet F. Impact of age and co-morbidity on the functioning of patients with sequelae of poliomyelitis: a cross-sectional study. J Rehabil Med 2007;39:56-62.
16. Ware JE, Gandek B. The SF-36® Health Survey: Development and use in mental health research and the IQOLA Project. Int J Ment Health 1994;23:49-73.
17. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care 2005;11 Suppl S459-64; quiz S465-8.
18. Schumacher HR Jr, Edwards LN, Perez-Ruiz F, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-5.
19. Schumacher HR, Taylor W, Joseph-Ridge N, et al. Outcome evaluations in gout. J Rheumatol 2007;34:1381-5.